140134-63-0

Basic information

• Product Name: N1-BENZYL-N1-ETHYL-PROPANE-1,3-DIAMINE
• Synonyms: N1-BENZYL-N1-ETHYL-PROPANE-1,3-DIAMINE;TIMTEC-BB SBB010879;N-(3-aminopropyl)-N-benzyl-N-ethylamine;ASINEX-REAG BAS 03363498
• CAS NO: 140134-63-0
• Molecular Formula: C₁₂H₂₀N₂
• Molecular Weight: 192.3
• Mol File: 140134-63-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N1-BENZYL-N1-ETHYL-PROPANE-1,3-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-BENZYL-N1-ETHYL-PROPANE-1,3-DIAMINE(140134-63-0)
• EPA Substance Registry System: N1-BENZYL-N1-ETHYL-PROPANE-1,3-DIAMINE(140134-63-0)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 140134-63-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N1-Benzyl-N1-Ethyl-Propane-1,3-Diamine is used as an intermediate compound for the synthesis of various pharmaceuticals targeting nervous system-related diseases. Its structural features allow for the development of drugs that can potentially modulate neurotransmitter activity, improve neuronal function, and alleviate symptoms associated with neurological disorders.
Used in Chemical Research:
In the field of chemical research, N1-Benzyl-N1-Ethyl-Propane-1,3-Diamine can be utilized as a building block for the creation of more complex molecules with specific properties. Its amine groups can be further functionalized or used in the formation of various chemical bonds, making it a valuable component in the synthesis of novel compounds with potential applications in materials science, drug development, and other areas of research.
Used in Material Science:
N1-Benzyl-N1-Ethyl-Propane-1,3-Diamine may also find applications in material science, particularly in the development of advanced polymers and materials with tailored properties. Its amine groups can be involved in the formation of cross-linking networks, which can enhance the mechanical strength, thermal stability, and other characteristics of the resulting materials.

Upstream product

• 100-52-7 benzaldehyde 
• 14321-27-8 N-ethylbenzylamine 
• 706-03-6 3-(benzylamino)propionitrile 
• 59629-66-2 N-benzyl-N-(2-cyano-ethyl)-acetamide 
• 906747-73-7 N-[3-(benzyl-ethyl-amino)-propyl]-2-nitro-benzenesulfonamide 

Downstream Products

• 125207-01-4 (E)-N-[3-(Benzyl-ethyl-amino)-propyl]-3-(4-nitro-phenyl)-acrylamide 
• 63636-31-7 N-[3-(Benzyl-ethyl-amino)-propyl]-2-[(E)-hydroxyimino]-acetamide 

Relevant articles and documents

DENTAL COMPOSITION

A dental composition comprising a polymerizable acidic compound of the following formula (I): wherein R1 which may be the same or different when more than one R1 is present, represents a hydrogen atom or a methyl group; R2 /sup

Design, synthesis and evaluation of scutellarein-O-acetamidoalkylbenzylamines as potential multifunctional agents for the treatment of Alzheimer's disease

A series of scutellarein-O-acetamidoalkylbenzylamines derivatives were designed based on a multitarget-directed ligands strategy for the treatment of Alzheimer's disease. Among these compounds, compound T-22 demonstrated excellent acetylcholinesterase inhibitory, moderate inhibitory effects on self-induced Aβ1-42 aggregation, Cu2+-induced Aβ1-42 aggregation, human AChE-induced Aβ1-40 aggregation and disassembled Cu2+-induced aggregation of the well-structured Aβ1-42 fibrils, and also acted as potential antioxidant and biometals chelator. Both kinetic analysis of AChE inhibition and molecular modeling study suggested that T-22 interacted with both the catalytic active site and peripheral anionic site of AChE. Moreover, compound T-22 showed a good neuroprotective effect against H2O2-induced PC12?cell injury and low toxicity in SH-SY5Y cells. Furthermore, the step-down passive avoidance test indicated T-22 significantly reversed scopolamine-induced memory deficit in mice. Taken together, the data showed that T-22 was an interesting multifunctional lead compound worthy of further study for AD.

Design, synthesis and evaluation of novel ferulic acid-memoquin hybrids as potential multifunctional agents for the treatment of Alzheimer's disease

A novel series of ferulic acid-memoquin hybrids were designed, synthesized and evaluated as multifunctional agents for the treatment of Alzheimer's disease (AD). The in vitro studies showed that most of the compounds exhibited a significant ability to inhibit acetylcholinesterase (AChE) (IC50 of 3.2-34.7 μM) and self-induced β-amyloid (Aβ1-42) aggregation (30.8-39.1%, 25 μM), to act as potential antioxidants (ORAC-FL value of 0.9-1.3). In particular, compound 17d had the greatest ability to inhibit AChE (IC50 = 3.2 μM), and Aβ1-42 aggregation (30.8%) was also an excellent antioxidant and neuroprotectant. Moreover, it is capable of disaggregating self-induced Aβ aggregation. Furthermore, 17d could cross the blood-brain barrier (BBB) in vitro. The results showed that compound 17d is a potential multifunctional agent for the treatment of AD.

Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease

A series of pterostilbene-O-acetamidoalkylbenzylamines were designed, synthesized and evaluated as dual inhibitors of AChE and BuChE. To further explore the multifunctional properties of the new derivatives, their antioxidant activities and inhibitory effects on self-induced Aβ1-42 aggregation and HuAChE-induced Aβ1-40 aggregation were also tested. The results showed that most of these compounds could effectively inhibit AChE and BuChE. Particularly, compound 21d exhibited the best AChE inhibitory activity (IC50 = 0.06 μM) and good inhibition of BuChE (IC50 = 28.04 μM). Both the inhibition kinetic analysis and molecular modeling study revealed that these compounds showed mixed-type inhibition, binding simultaneously to the CAS and PAS of AChE. In addition to cholinesterase inhibitory activities, these compounds showed different levels of antioxidant activity. However, the inhibitory activities against self-induced and HuAChE-induced Aβ aggregation of these new derivatives were unsatisfied. Taking into account the results of the biological evaluation, further modifications will be designed in order to increase the potency on the different targets. The results displayed in this Letter can be a new starting point for further development of multifunctional agents for Alzheimer's disease.

Design, synthesis and evaluation of chromone-2-carboxamido-alkylbenzylamines as multifunctional agents for the treatment of Alzheimer's disease

A series of chromone-2-carboxamido-alkylbenzylamines were designed, synthesized and evaluated as multifunctional agents for the treatment of Alzheimer's disease (AD). The results showed that most of these compounds exhibited good multifunctional activities. Among them, compound 49 displayed excellent inhibitory potency toward acetylcholinesterase (AChE), moderate anti-oxidative activity, selective biometal chelating, and possessed good inhibitory effects on self-induced and Cu2+-induced Aβ aggregation. Both kinetic analysis of AChE inhibition and molecular modeling study indicated that 49 was a mixed-type inhibitor, binding simultaneously to the catalytic active site and peripheral anionic site of AChE. These results suggested that 49 might be a potential multifunctional agent for AD treatment.

Efficient, asymmetric synthesis of (-)-isooncinotine

Asymmetric synthesis of (-)-isooncinotine, a 22-membered lactam of spermidine alkaloid, starting from resolution of 2-piperidineethanol with (S)-10-camphorsulfonic acid is reported. Michael addition, amidations, and aluminum hydride reduction were applied to form the moiety of spermidine. Retro-Michael addition was observed when β-amido- and β-amino-propionitriles were reduced by LAH. The effects of LAH versus AlH3 were discussed. The synthesis of the skeleton of this macrolide is achieved with ring-closing metathesis of the?diene prepared from acylation of the spermidine.

Parallel synthesis of 9-aminoacridines and their evaluation against chloroquine-resistant Plasmodium falciparum

A parallel synthetic strategy to the 9-aminoacridine scaffold of the classical anti-malarial drug quinacrine (2) is presented. The method features a new route to 9-chloroacridines that utilizes triflates of salicylic acid derivatives, which are commercially available in a variety of substitution patterns. The route allows ready variation of the two diversity elements present in this class of molecules: the tricyclic aromatic heterocyclic core, and the disubstituted diamine sidechain. In this study, a library of 175 compounds was designed, although only 93 of the final products had purities acceptable for screening. Impurity was generally due to incomplete removal of 9-acridones (18), a degradation product of the 9-chloroacridine synthetic intermediates. The library was screened against two strains of Plasmodium falciparum, including a model of the drug-resistant parasite, and six novel compounds were found to have IC50 values in the low nanomolar range.